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Duchenne muscular dystrophy (DMD) is a devastating X-linked muscle disorder characterized by muscle wasting which is caused
by mutations in the DMD gene. The DMD gene encodes the sarcolemmal protein dystrophin, and loss of dystrophin causes muscle
degeneration and necrosis. Thus far, therapies for this disorder are unavailable. However, various therapeutic trials based on gene
therapy, exon skipping, cell therapy, read through therapy, or pharmaceutical agents have been conducted extensively. In the
development of therapy as well as elucidation of pathogenesis in DMD, appropriate animal models are needed. Various animal
models of DMD have been identiﬁed, and mammalian (murine, canine, and feline) models are indispensable for the examination
of the mechanisms of pathogenesis and the development of therapies. Here, we review the pathological features of DMD and
therapeutic applications, especially of exon skipping using antisense oligonucleotides and gene therapies using viral vectors in
murine and canine models of DMD.
1.Introduction
Duchenne muscular dystrophy (DMD) is a lethal X-linked
muscle disease characterized by progressive skeletal muscle
atrophy and weakness [1]. Mutations in the causative gene
DMD result in loss of the cytoskeletal protein dystrophin.
This is accompanied by a defect of dystrophin-glycoprotein
complex (DGC) in the sarcolemma and leads to progres-
sive muscle degeneration [2, 3]. The dystrophic-deﬁcient
skeletal muscle exhibits muscle ﬁber necrosis with invasion
of inﬂammatory cells followed by muscle regeneration.
The muscle is progressively replaced by ﬁbrous or fatty
tissue. Recent advances in molecular biology have identiﬁed
murine, canine, and feline DMD animal models [4]. Eﬀorts
to develop various therapeutic approaches such as gene
therapy, cell therapy, or pharmaceutical agents have been
conducted using DMD animal models, although no radical
and permanent therapy is available. In this review, we
describe the pathological characteristics and availability of
therapeutic applications with a focus on gene therapy in
mammalian models of DMD.
2. DuchenneMuscular Dystrophy
2.1. Pathogenesis of DMD. Muscular dystrophies are inher-
ited, and progressive muscle disorders are characterized by
muscle ﬁber degeneration and necrosis. Duchenne muscular
dystrophy (DMD) is the most severe and common X-linked
disorder (1 in 3,500 male births) [1]. The onset of this
disorder is recognized by observation of walking diﬃculties
experienced by children between 2 and 5 years of age.
The skeletal muscle degeneration is progressive, resulting in
patients being wheelchair bound by the age of 13. DMD
patients tend to die by the age of about 30 as a result of
respiratory or cardiac failure [1].
DMD is caused by a mutation in the DMD gene, which
is one of the largest in the human genome (approximately
2.5 million base pairs, encoding 79 exons). Full-length2 Journal of Biomedicine and Biotechnology
dystrophin mRNA is approximately 14kb and is mainly
expressed in skeletal, cardiac, and smooth muscles, as well
as in the brain [2]. The dystrophin protein encoded by
the DMD gene is rod shaped and consists of 4 domains:
the N-terminal actin-binding domain, a rod-shaped domain
composed of 24 spectrin-like rod repeats and 4 hinges, a
cysteine-rich domain that interacts with dystroglycan and
sarcoglycan complexes, and the C-terminal domain that
interacts with the syntrophin complex and dystrobrevin
[3]. Dystrophin is localized at the sarcolemma and forms
a dystrophin-glycoprotein complex (DGC) with dystrogly-
can, sarcoglycan, and syntrophin/dystrobrevin complexes.
These associations link the cytoskeletal protein actin to
the basal lamina of muscle ﬁbers [3]. DGC is thought to
act as a membrane stabilizer during muscle contraction
or a transducer of signals from the extracellular matrix to
the muscle cytoplasm via intracellular signaling molecules.
Loss of dystrophin leads to conditions under which the
membrane becomes leaky as a result of mechanical or hypo-
osmotic stress. Consequently, Ca2+ permeability is increased
and various Ca2+ dependent proteases such as calpain are
activated under conditions of dystrophin deﬁciency. It has
also been proposed that alteration of the expression or
function of the plasma membrane proteins associated with
dystrophin such as neuronal nitric oxide synthase (nNOS)
and various ion channels are involved in the molecular
mechanisms of muscle degeneration [5].
The DMD gene mutations include missense, nonsense,
deletion, insertion, or duplication mutations. When a muta-
tion of DMD disrupts the reading frame of amino acids (an
out-of-frame mutation), the dystrophin defect results in the
severe DMD phenotype. On the other hand, a mutations
which maintains the reading frame (an in-frame mutation)
tends to produce a truncated but functional dystrophin,
which leads to the more benign phenotype known as Becker
muscular dystrophy (BMD). About 90% of cases of the phe-
notypes of DMD and BMD can be explained by this frame-
shift theory [6]. There are two major hot spots for mutations
around exons 3–7 and exons 45–55 in the DMD gene [6].
2.2. Investigations of Gene Therapy for Treatment of DMD.
For the treatment of DMD, various experimental approaches
such as gene therapy using viral vectors, exon-skipping
therapy,stemcelltransplantation,read-throughtherapy,and
pharmacological agents have been extensively developed, but
none of these have met with success in the clinic. Among
these therapeutic strategies, exon skipping using antisense
oligonucleotides (AOs) has been considered to be one of the
most promising therapies for the restoration of dystrophin
expression at the sarcolemma in dystrophin-deﬁcient mus-
cle. Exon skipping as treatment for DMD is developed based
on the frame-shift theory. AOs are chemically-synthesized
single-strand nucleic acids about 25 bases in length which
are designed to recognize a speciﬁc sequence of the mRNA
splicing pattern or of the binding protein. These agents can
artiﬁcially change the translation of the nucleic acid. Among
the various types of AOs, the 2 -O-methyl phosphorothioate
AO (2OMeAO) and the phosphorodiamidate morpholino
oligomers (PMO: morpholino) have high eﬃcacy, low
toxicity, and high stability [7, 8]. Therefore, exon skipping
strategies mediated by 2OMeAO and PMO have been exten-
sively performed and clinical studies have been conducted.
Gene therapy using viral vectors has been extensively
investigated. Adeno-associated virus (AAV) vectors are the
most appropriate tools for viral vector gene therapy because
they are nonpathogenic due to a replication defect and have
low immunity with an eﬀective ability to infect nondividing
cells. This strategy, however, is limited with respect to the
size of the inserted exogenous gene. The upper limit of
4.9kb prevents the full-length DMD cDNA (14kb) from
being successfully incorporated into the vector. Our group
and other researchers have designed a shorter but functional
microdystrophin, which is driven by the muscle-speciﬁc cre-
atine kinase (MCK) promoter in combination with AAV vec-
tors of various serotypes. The eﬃcacy of this system has been
examined [9, 10], and it has been found that the immune
reaction is one of the critical issues in canine or primates.
Other serotypes of AAV with a weaker immune reaction,
suchasAAV8,haverecentlybeendeveloped.TheserAAVsare
capable of providing powerful systemic delivery of the DMD
gene to muscles throughout the body, including the heart.
3. Mammalian Models of DMD
Animal models are needed for elucidation of the patho-
genesis and assessment of eﬃcacy and toxicity during the
development of therapies. In DMD, various animal models
havebeenidentiﬁedandutilized.Inthisreview,weintroduce
and discuss not only the pathological characteristics of
mammalian (murine, feline, or canine) models of DMD but
also recent advances in therapeutic applications using these
models.
4. MurineModel of DMD
Various mouse models with mutations in the mouse DMD
gene have been identiﬁed: X-linked muscular dystrophy
mouse (mdx)[ 11] and 4 additional strains of mdx mouse—
mdx2cv, mdx3cv, mdx4cv, or mdx5cv mouse [12]. Moreover,
the DMD exon 52 knockout (mdx52) mouse [13]a n d
the mdx mouse with additional ablation of the dystrophin
homologue utrophin (mdx/utr−/−)[ 14]w a sp r o d u c e d .
Among these models, the mdx mouse is the most commonly
used model. The mouse models are indispensable for eluci-
dation of the pathogenic mechanism and for development of
therapeutic approaches, since they can be easily and reliably
reproduced. In this section, we introduce the pathological
features of mdx and mdx52 mice and the availability of
therapeutic approaches which have beneﬁted from the use
of these mouse models.
4.1. Mdx Mice
4.1.1. Pathological Characteristics. X-linked muscular dys-
trophy mouse (mdx) was found to spontaneously occur
in a C57BL/10 strain [15], and a nonsense mutation was
i d e n t i ﬁ e di ne x o n2 3o ft h eDMD gene. This mutation causes
a lack of dystrophin at the sarcolemma [2]. A previous
study using mdx mice revealed that muscle necrosis withJournal of Biomedicine and Biotechnology 3
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Figure 1: (a) A male mdx52 mouse at 6 weeks of age. The
generalizedappearanceisalmostnormal.(b)Thepathology(Hand
E) of the tibialis anterior muscle shows multicentrally nucleated
ﬁbers with an increased extent of invasion of inﬂammatory cells
and the interstitial space. Hypertrophic muscle ﬁbers were also
observed.
inﬁltration of neutrophils or macrophages is recognized at
approximately 2 weeks of age and that a massive muscle
degeneration/necrosis occurs at approximately 1 month of
age. Muscles continue to go through cycles of necrosis and
regeneration throughout the lifespan of the mdx mouse; it is
just that is slows and is milder after 12 weeks. Necrotic ﬁbers
canbefoundatanyageandappearwithincreasingfrequency
after 18 months of age and the pathology progresses. The
muscle pathology is most pronounced between 2 and 8
weeks of age. This period is characterized by the presence
of extensive necrosis, regenerated centrally nucleated ﬁbers,
and high levels of serum creatine kinase (CK), a biochemical
marker of muscle necrosis [11, 15]. The skeletal and cardiac
muscle deterioration of the mdx mouse is relatively much
milder than that of human cases of DMD [16, 17]. As a
result, the ﬁbrosis and inﬁltration of inﬂammatory cells in
the skeletal muscle at later stages tend to be much less than
that observed in DMD patients.
4.1.2. Therapeutic Applications. Recent advances in thera-
peutic applications include exon skipping, gene therapy, and
cell therapy. In the development of exon skipping therapy,
themdx mouseisavailableforexon23skippingtoconvertan
out-of-frame mutation into an in-frame mutation. Systemic
administration of 2 -O-methyl phosphorothioate antisense
oligonucleotides (2OMeAO) with a nonion polymer F127
to mdx mice revealed that dystrophin is expressed in the
whole-body skeletal muscle with the exception of heart
muscle. However, the 2OMeAO did not reach a therapeutic
level [18]. Meanwhile, systemic induction of dystrophin
expression by phosphorodiamidate morpholino oligomers
(PMO: morpholino) in the mdx mouse reached a treatable
level in whole-body skeletal muscle with the exception
of the heart [19, 20]. The peptide-linked PMO (PPMO)
induced high expression of dystrophin not only in whole-
body skeletal muscles but also in the heart in mdx mice [21].
A unique exon-skipping method was proposed in which the
mutated exon 23 on the mRNA of mdx mice is removed by a
single administration of an AAV vector expressing antisense
sequences linked to a modiﬁed U7 small nuclear RNA [22].
In the development of gene therapy, we and other groups
have designed a shorter but functional microdystrophin
to incorporate into the recombinant AAV2 (rAAV2). The
microdystrophin, which has a large deletion in the central
rod domain, was constructed on the basis of the sequence
of the mutated DMD gene in a BMD patient with a nearly
normal life expectancy. The expression of this construct
was driven by the muscle-speciﬁc creatine kinase (MCK)
promoter, and local and systemic delivery of rAAV2 was
found to restore the muscle function and life span of mdx
mice [8, 9]. The other serotypes—rAAV6 [23], rAAV8 [24],
and rAAV9 [25]—are also expected to be useful for systemic
delivery of the DMD gene.
Although certain issues such as body size, genetic
background, and pathological features should be addressed,
the mdx mouse has been indispensable as a DMD model for
development of therapeutic approaches.
4.2. Mdx52 Mouse
4.2.1. Pathological Characteristics. Katsuki and colleagues
successfully generated a new DMD mouse model known as
mdx52. In this model, exon 52 of the murine DMD gene was
deleted using a homologous recombination technique [13].
Like the mdx mouse, mdx52 lacks dystrophin and presents
d y s t r o p h i cc h a n g e sw i t hm u s c l eh y p e r t r o p h y( Figure 1). In
particular, the retina-speciﬁc dystrophin isoform Dp260 is
absent and abnormalities were observed in electroretino-
graphic analyses [26].
4.2.2. Therapeutic Applications. The targeting of exon 51
for exon skipping is theoretically applicable to the high-
est percentage (13%) of DMD patients with an out-of
frame deletion mutation [27–29]. An in-frame dystrophin
mutation performed by an exon 51 skipping technique via
local intramuscular injection of 2OMeAOs was found to be
successful in some patients with DMD [30, 31]. Recently, we
conducted exon 51 skipping using PMO in mdx52 mice to
convertanout-of-framemutationintoanin-framemutation
and examined muscle function. The results showed that
dystrophin expression was restored in whole-body skeletal
muscles with amelioration of the dystrophic pathology and4 Journal of Biomedicine and Biotechnology
improved muscle function [32]. Thus, mdx52 has proven to
be useful for development of the exon skipping technique
and was used to obtain proof of concept for ongoing clinical
trials.
5.CanineModel of DMD
Several diﬀerent canine models of DMD have been reported
thus far [4]. Mutations of the canine DMD gene were
i d e n t i ﬁ e di nG o l d e nR e t r i e v e r[ 33], Rottweiler [34], German
Short-Hair Pointer [35], and Cavalier King Charles Spaniels
[36]. Golden Retriever muscular dystrophy (GRMD) has
been the most extensively examined and characterized. We
recently described Beagle-based canine X-linked muscular
dystrophy (CXMDJ) and conducted many studies on the
elucidation of pathogenesis and the development of thera-
peutic approaches using this model. Exon-skipping therapy
has been investigated using Cavalier King Charles Spaniels
with muscular dystrophy (CKCS-MD). In this section, we
describe the pathological characteristics and availability of
gene therapies for GRMD, CXMDJ, and CKCS-MD.
5.1. Golden Retriever Muscular Dystrophy (GRMD)
5.1.1.PathologicalCharacteristics. GRMDischaracterizedby
progressive skeletal muscle weakness and atrophy as well
as cardiac involvement. These characteristics are similar to
those of DMD. GRMD is caused by a point mutation at the
intron 6 splice acceptor site of the canine DMD gene. This
causes skipping of exon 7 and a premature stop codon in
exon 8 and results in a lack of dystrophin [33]. The level
of serum CK is dramatically increased early at 1-2 days of
age and extensive diaphragm damage is observed [37]. The
clinical manifestations of GRMD are progressive with the
gradual loss of muscle mass and contractures that often lead
to skeletal deformities [37]. Extensive muscle degeneration
and necrosis of generalized muscles are identiﬁed from birth
onwards [38]. A distinct feature is enlargement of the base
of the tongue, pharyngeal muscle, and esophagus, resulting
in dysphagia, drooling, and regurgitation. Severe ﬁbrosis
in muscle and joint contracture develops by 6 months of
age [33], and respiratory failure or cardiomyopathy are
frequently observed at younger ages [39]. GRMD is further
characterized by progressive cardiomyopathy as indicated by
deeperandnarrower Qwavesin leadsII,III,andaVF relative
to cardiac involvement in human DMD patients [38, 40, 41].
The skeletal and cardiac characteristics of GRMD are
more similar to those of DMD than of mdx. The genetic
background and body size of the Golden Retriever is closer
to human than the mouse. Therefore, GRMD has been
considered to be a useful animal model for human DMD in
recent years.
5.1.2. Therapeutic Applications. Preliminary gene therapy
experiments on GRMD performed using adenovectors [42],
and high expression of a dystrophin minigene was achieved
inGRMDusingreplication-deﬁcientadenoviralvectors[43].
Very recently, systemic delivery of the AAV9 human mini-
dystrophin vector induced widespread muscle expression of
the transgene in neonatal dystrophic dogs [44].
In exon-skipping therapy, prolonged maintenance of
functional dystrophin in GRMD muscle has additionally
been achieved through chimeric RNA/DNA oligonucleotide
therapy [45]. GRMD muscle cells were observed in order to
compare the eﬀe c t i v e n e s so f2 O M eA O ,P M O ,o rp e p t i d e -
linkedPMO(PPMO)[46].ThePPMOwasfoundtobecapa-
ble of inducing high and sustained levels of exon skipping
and induced the highest level of dystrophin expression with
no apparent adverse eﬀects upon the cells.
5.2. Canine X-Linked Muscular Dystrophy (CXMDJ)
5.2.1. Pathological Characteristics. As described in the previ-
ous section, GRMD is well characterized and attractive for
research on DMD. However, Golden Retrievers are too large
to be treated or raised easily and animal trials employing
these dogs have substantial animal welfare implications and
high costs associated with both maintenance and treatment.
To address these issues, we developed a strain of medium-
sized dystrophic Beagles by artiﬁcial insemination of two
females with thawed spermatozoa obtained from a Golden
Retriever with GRMD followed by interbreed crossing of the
carrier female dogs with Beagle sires [47]. We designated the
dystrophic dogs as canine X-linked muscular dystrophy in
Japan (CXMDJ). The colony is maintained at the General
AnimalResearchFacilityoftheNationalCenterofNeurology
and Psychiatry in Tokyo [47]. The serum CK level of
dogs with CXMDJ at birth is very high, and the mortality
rate during the neonatal period is about 32.3%. This is
signiﬁcantly higher than that of normal littermates (13.3%).
Diaphragm muscle involvement occurs shortly after birth
and is more severe than that of limb muscles. At an age of
about 2-3 months, atrophy and weakness of limb muscles
appear, followed by development of macroglossia, dysphasia,
gait disturbance, and joint contracture from 4 months
of age. These symptoms rapidly progress until about 10
months of age, after which the progression of the disease is
retarded [48]. The clinical manifestations of third generation
CXMDJ aresimilarbutmilderthanthoseobservedinGRMD
(Figure 2).
In the cardiac manifestation, GRMD as well as DMD
have particular characteristics such as distinct deep electro-
cardiogram Q-waves and ﬁbrosis of the left ventricular wall
[38, 40, 41]. We regularly examined the cardiac performance
of the CXMDJ model by electrocardiogram, echocardio-
gram, and pathology and found that the deep Q-waves on
echocardiograms precede the development of overt ﬁbrosis
in histopathology [49]. So far, the pathogenic mechanism
of the distinct deep Q-waves has been considered to be
ascribed to ﬁbrosis in the posterobasal region of the left
ventricular wall in DMD [41]. When we investigated the
cardiac conduction system of CXMDJ,ar e m a r k a b l ee x t e n t
of vacuolar degeneration was observed in Purkinje ﬁbers
despite the absence of detectable ﬁbrotic lesions in the ven-
tricular myocardium [50]. The degenerated Purkinje ﬁbersJournal of Biomedicine and Biotechnology 5
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Figure 2: (a) A male canine with X-linked muscular dystrophy
(CXMDJ) at 6 months of age. The atrophy of muscles throughout
the body (including temporal muscle) is observed. Kyphosis,
abnormal sitting posture, and contracture of hindlimb joints are
seen. (b) The pathology (H and E) of tibialis cranialis muscle
indicates muscle necrosis with inﬁltration of inﬂammatory cells,
centrally nucleated ﬁbers, and increased interstitial connective
tissues.
were coincident with overexpression of Dp71 (a C-terminal
truncated isoform of dystrophin) at the sarcolemma and
translocation of μ-calpain (a calcium-dependent protease)
to the periphery near the sarcolemma or to the vacuoles.
Utrophin, a homologue of dystrophin was upregulated in
dystrophin deﬁciency. Utrophin was found to be highly
upregulated in the Purkinje ﬁbers in the early stage, but
the expression was dislocated when vacuolar degeneration
was recognized at 4 months of age. Based on these ﬁndings,
we hypothesized that the selective degeneration of Purkinje
ﬁberscouldbeassociatedwithdistinctdeepQ-wavesonelec-
trocardiogramsandthefatalarrhythmiawhichisobservedin
dystrophinopathy [50]. Thus, our previous investigations of
the clinical phenotype in CXMDJ revealed not only that the
phenotypes are nearly identical to those of GRMD but also
that the model will play a useful role in elucidation of the
pathogenic mechanism and in development of therapeutic
approaches.
5.2.2. Therapeutic Applications. Recently, in conjunction
with our collaborators at the Children’s National Medical
Center in the USA, we developed a multiexon-skipping
technique for targeting exons 6 and 8 to convert an
out-of-frame mutation into an in-frame mutation using
PMOs. Systemic multiexon-skipping treatment in CXMDJ
was found to restore dystrophin in the whole-body skeletal
muscle (with the exception of heart). Furthermore, skeletal
muscle function was notably improved without any adverse
eﬀects [51]. This represents the ﬁrst report on successful in
vivo multiexon-skipping. Furthermore, we have succeeded
in producing multiexon skipping by administration of the
PMOsusedinCXMDJ toMyoD-transduced ﬁbroblastsfrom
a DMD patient with the exon 7 deletion of the DMD gene
[52]. This suggests that multiexon skipping is feasible for
treatment of DMD patients and that this approach could be
applicable to up to 83% of all DMD patients [27].
To examine therapeutic eﬀects and safety in a larger
animal model, we have examined the eﬃciency of rAAV2
infection of canine myotubes and expression of the lacZ
gene into normal canine muscle. In contrast to the results
of mdx investigations, the rAAV2-mediated gene transfer
was found to elicit a severe immune response against
the AAV particle, and its gene product in the host [53].
We, therefore, have examined the transgene expression and
host immune response to two diﬀerent rAAV (rAAV2 and
rAAV8) in normal canine and in the CXMDJ model after
intramuscular injection and systemic administration by limb
perfusion to bypass the immune activation of dendritic
cells in the injected muscle. In contrast to the results with
rAAV2 transduction, intramuscular transduction of rAAV8-
lacZ in normal dogs and systemic administration of rAAV8-
microdystrophin in CXMDJ were found to improve the
expression of both transgenes in the skeletal muscle [54].
The CXMDJ model led us to propose that rAAV8-mediated
transduction strategy could have a therapeutic advantage in
DMD gene therapy.
Thus, the clinical phenotype of CXMDJ has been well
characterized as an appropriate animal model and the
similarity of pathology of DMD is regarded as the most
appropriate model for DMD in clinical trials. Other thera-
peutic approaches will be evaluated in the dog model with a
view to establishing feasible protocols.
5.3. Cavalier King Charles Spaniels with Muscular
Dystrophy (CKCS-MD)
5.3.1. Pathological Characteristics. Very recently, it was repo-
rted that another dystrophic dog, the Cavalier King Char-
les Spaniel with dystrophin-deﬁcient muscular dystrophy
(CKCS-MD) has a severe phenotype. This canine model has
a missense mutation in the 5  donor splice site of exon 50
resulting in deletion of exon 50 in mRNA transcripts and
a predicted premature truncation of the translated protein
[36].
5.3.2. Therapeutic Applications. The therapeutic strategy of
exon skipping in the GRMD or CXMDJ models provides
a signiﬁcant advantage in clinical trials, but also has the
unfavorable characteristic that the disease-causing mutation
does not include the region of the DMD gene that is most
commonly mutated in human DMD patients. About 60% of6 Journal of Biomedicine and Biotechnology
DMD patients harbor deletions in exons 45–55 of the DMD
gene [55, 56]. As described previously, the exon 51 skipping
technique, which is being employed in clinical trials [30, 31],
is applicable to DMD patients which have deletions of exon
50, exon 52, exons 48–50, or exons 49-50, among others, and
is feasible for more patients than other exon skipping strate-
gies [27, 57, 58]. AO-mediated skipping of exon 51 in cul-
tured myoblasts of the CKCS-MD dog restored the reading
frame and protein expression [17]. This observation suggests
that the use of this canine model would be valuable in the
preclinical trials of therapy based upon exon 51 skipping.
6. FelineModel of DMD
6.1. Hypertrophy Feline Muscular Dystrophy (HFMD). Feline
muscular dystrophy with dystrophin deﬁciency has been
identiﬁed [59]. This feline model has a unique phenotypic
expression of hypertrophy of the tongue, neck, and shoulder
muscles, lingual calciﬁcation, excessive salivation, megae-
sophagus, gait disturbance manifesting as bunny hopping,
dilated cardiomyopathy, hepatosplenomegaly and kidney
failure [60, 61]. These dystrophic cats have been described
as having hypertrophic feline muscular dystrophy (HFMD)
because of the distinct hypertrophic feature. The pathology
exhibits muscle degeneration and centrally nucleated regen-
eration and accumulation of calcium deposits within muscle
ﬁbers without development of ﬁbrosis. The HFMD cat has
a large deletion of muscle and Purkinje promoters resulting
in a lack of dystrophin in the skeletal and cardiac muscle
[62]. However, the dystrophic cats have not been widely used
as a DMD model due to the limited pathological similarity
to DMD [4]; there have been no reports on therapeutic
approaches using this feline model.
7. Conclusions
Murine models will continue to provide important ﬁndings
for the basic study of pathogenesis and development of
therapies, but the clinical phenotype is mild and this is a
weak point. On the other hand, canine models have severe
skeletal and cardiac defects resembling DMD and the body
size and genetic background of canines are more similar to
human beings than the murine models. We are, therefore,
convinced that canine models will be more useful for
future contributions to preclinical study of newly developed
therapies.
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